Carisoprodol - Generic Drug Details

What are the generic sources for carisoprodol and what is the scope of freedom to operate?

Carisoprodol is the generic ingredient in three branded drugs marketed by Mylan Speciality Lp, Able, Accelrx Labs, Allied, Aurobindo Pharma, Chartwell Rx, Epic Pharma Llc, Hikma Intl Pharms, Natco, Nostrum Labs Inc, Novast Labs, Orient Pharma Co Ltd, Oxford Pharms, Pioneer Pharms, Sandoz, Sciegen Pharms Inc, Strides Pharma, Sun Pharm Inds Ltd, Sun Pharm Industries, Wanbang Biopharms, Watson Labs, Watson Labs Teva, and Schering, and is included in twenty-six NDAs. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for carisoprodol. Twenty-seven suppliers are listed for this compound.

Summary for carisoprodol

US Patents:	0
Tradenames:	3
Applicants:	23
NDAs:	26
Drug Master File Entries:	16
Finished Product Suppliers / Packagers:	27
Raw Ingredient (Bulk) Api Vendors:	83
Clinical Trials:	4
Patent Applications:	6,487
Drug Prices:	Drug price trends for carisoprodol
What excipients (inactive ingredients) are in carisoprodol?	carisoprodol excipients list
DailyMed Link:	carisoprodol at DailyMed

See drug prices for carisoprodol

See drug sales revenues for carisoprodol

Recent Clinical Trials for carisoprodol

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ache Laboratorios Farmaceuticos S.A.	Phase 3
Farmoquimica S.A.	Phase 3
Pharmagenix Projetos em Medicina Farmacêutica Ltda.	Phase 3

See all carisoprodol clinical trials

Pharmacology for carisoprodol

Drug Class	Muscle Relaxant
Physiological Effect	Centrally-mediated Muscle Relaxation

Medical Subject Heading (MeSH) Categories for carisoprodol

Muscle Relaxants, Central

Anatomical Therapeutic Chemical (ATC) Classes for carisoprodol

M03BA	Carbamic acid esters
M03B	MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
M03	MUSCLE RELAXANTS
M	Musculo-skeletal system

US Patents and Regulatory Information for carisoprodol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novast Labs	CARISOPRODOL	carisoprodol	TABLET;ORAL	040823-001	Oct 22, 2008	AA	RX	No	No
Nostrum Labs Inc	CARISOPRODOL	carisoprodol	TABLET;ORAL	207237-002	Sep 21, 2020	AA	RX	No	No
Allied	CARISOPRODOL	carisoprodol	TABLET;ORAL	211789-001	Oct 20, 2021		DISCN	No	No
Strides Pharma	CARISOPRODOL	carisoprodol	TABLET;ORAL	205513-001	Nov 12, 2015		DISCN	No	No
Nostrum Labs Inc	CARISOPRODOL	carisoprodol	TABLET;ORAL	207237-001	May 11, 2017	AB	RX	No	No

Carisoprodol Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Carisoprodol

Introduction to Carisoprodol

Carisoprodol, commonly known by the brand name Soma, is a muscle relaxant used to alleviate pain and discomfort caused by strains, sprains, and other muscle injuries. It is part of a broader class of skeletal muscle relaxants that have seen significant market growth in recent years.

Market Size and Growth

The global carisoprodol market is part of the larger muscle relaxant drugs market, which has been experiencing robust growth. As of 2023, the muscle relaxant drugs market was valued at $4.46 billion and is projected to grow to $4.83 billion in 2024, with a compound annual growth rate (CAGR) of 8.2%[3].

For carisoprodol specifically, the market size is estimated to grow significantly from 2019 to 2031. The 250mg segment of carisoprodol tablets accounted for a noticeable share of the global market in 2023 and is expected to experience significant growth in the near future[1].

Segmentation and Analysis

By Drug Type

The muscle relaxant market, including carisoprodol, is segmented into facial muscle relaxant drugs, skeletal muscle relaxant drugs, and neuromuscular blocking agents. Skeletal muscle relaxants, which include carisoprodol, are a key segment driving market growth due to their widespread use in managing musculoskeletal disorders[3].

By Formulation

Carisoprodol is one of the key formulations in the muscle relaxant market, alongside other drugs such as cyclobenzaprine, chlorzoxazone, and metaxalone. The formulation segment analysis helps in understanding the market share and growth potential of carisoprodol compared to other muscle relaxants[3].

By Route of Administration

Carisoprodol is primarily administered orally, which is the dominant route of administration in the muscle relaxant market. This segment is expected to continue its dominance due to the ease of administration and patient compliance[3].

By End-User

The end-user segment includes hospitals, homecare, specialty clinics, and other end-users. The hospital segment is expected to expand at a significant CAGR, retaining its position throughout the forecast period, which positively impacts the demand for carisoprodol[1][3].

Market Drivers

Chronic Pain Management

The rising incidence of musculoskeletal disorders, including chronic pain and muscle spasms, has driven the demand for effective medications like carisoprodol. An aging population and increased sedentary lifestyles contribute to this trend[4].

Pharmaceutical Innovation

Innovations in drug formulations and the development of new muscle relaxants have contributed to market growth. The integration of muscle relaxants into pain management protocols and advancements in pain management therapies are key drivers[3].

Aging Population and Chronic Conditions

The aging population and the increasing prevalence of chronic conditions such as arthritis and other musculoskeletal disorders are driving the demand for muscle relaxants like carisoprodol[3].

Market Restraints

Regulatory Challenges

Carisoprodol, like other muscle relaxants, faces regulatory challenges. Its potential for abuse and dependency has led to stricter regulations and monitoring, which can impact market growth[5].

Competition from Generic Drugs

The introduction of generic alternatives can reduce the market share of branded carisoprodol. The "patent cliff" period, during which major blockbuster drugs lose their patent protection, has seen a shift towards generic drugs, which can restrain the growth of branded carisoprodol sales[2].

Regional Analysis

The global carisoprodol market is segmented into several major regions, including North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America was the largest region in the muscle relaxant drugs market share in 2023, with significant contributions from the United States and Canada[1][3].

Competitor Analysis

Key companies in the carisoprodol market include Cadista Pharmaceuticals and Endo Pharmaceuticals. These companies are focusing on strategy building models to strengthen their product portfolios and expand their business in the global market. For example, Corona Remedies' acquisition of the muscle relaxant brand Myoril from Sanofi India highlights the strategic moves companies are making to fortify their positions in the market[1][3].

Financial Trajectory

The financial trajectory of the carisoprodol market is positive, with significant growth projected over the next few years. Here are some key financial indicators:

• Market Size: The global carisoprodol market size is estimated to grow from 2019 to 2031, with the 250mg segment expected to experience significant growth[1].
• CAGR: The muscle relaxant drugs market, which includes carisoprodol, is expected to grow at a CAGR of 7.9% from 2023 to 2028[3].
• Revenue: The muscle relaxant market is expected to reach $6.55 billion by 2028, indicating a strong financial trajectory for carisoprodol as part of this market[3].

Technological and Pharmaceutical Trends

Advancements in Pain Management

Advancements in pain management therapies, including the integration of muscle relaxants into pain management protocols, are driving the market forward. Research in targeted therapies and the focus on non-pharmacological pain relief are also contributing to the growth of the carisoprodol market[3].

Personalized Medicine Approach

The trend towards personalized medicine is expected to influence the muscle relaxant market, including carisoprodol. This approach could lead to more effective and tailored treatments, further boosting market growth[3].

Key Takeaways

• The global carisoprodol market is part of the growing muscle relaxant drugs market.
• Market growth is driven by chronic pain management, pharmaceutical innovation, and an aging population.
• The 250mg segment of carisoprodol tablets is expected to experience significant growth.
• Regulatory challenges and competition from generic drugs are key restraints.
• North America is the largest region in the muscle relaxant drugs market.
• Key companies are focusing on strategic acquisitions and product portfolio strengthening.

FAQs

1. What is the primary use of carisoprodol? Carisoprodol is primarily used as a muscle relaxant to alleviate pain and discomfort caused by strains, sprains, and other muscle injuries.

2. What are the key drivers of the carisoprodol market? The key drivers include chronic pain management, pharmaceutical innovation, and an aging population with increasing chronic conditions.

3. Which region dominates the carisoprodol market? North America is the largest region in the muscle relaxant drugs market, including carisoprodol.

4. What are the potential restraints for the carisoprodol market? Regulatory challenges due to its potential for abuse and dependency, and competition from generic drugs, are significant restraints.

5. What is the projected CAGR for the muscle relaxant drugs market? The muscle relaxant drugs market, which includes carisoprodol, is expected to grow at a CAGR of 7.9% from 2023 to 2028.

Cited Sources

1. Global Carisoprodol Tablet Market Report 2024 Edition - Cognitivemarketresearch.com
2. Review of Prescription Drug Costs and Summary of Potential Strategies - Hca.wa.gov
3. Muscle Relaxant Drugs Global Market Report 2024 - Thebusinessresearchcompany.com
4. Carisoprodol (Soma) Manufacturing Plant Report 2024 - IMARC Group
5. Critical review report Carisoprodol - World Health Organization (WHO)